20 March, 11am, Seminar room 3, TRF level 2
Synopsis: The last several years has seen the approval of multiple new therapies for advanced prostate cancer that target the androgen receptor (AR) axis. Despite improvements in clinical outcomes, resistance to these agents is inevitable. This project aims to design and implement a highly sensitive next-generation sequencing assay capable of identifying prostate-cancer associated mutations in patient circulating tumour DNA (ctDNA) in order to understand therapeutic response and resistance.
Supervisors: A/Prof Arun Azad, Prof Melissa Southey
3 comments
commentsThanks for posting the useful information to my vision. This is excellent information,.
ReplyHotel Frankfurt Oder
This is a great post. I like this topic.This site has lots of advantage. It helps me in many ways.Thanks for posting this again. Hotel Frankfurt-Oder
Reply
ReplyWORD WHIZZLE SEARCH BABY